A study finds a pan-coronavirus antibody that targets a conserved epitope, which is exposed during SARS-CoV-2 fusion.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274630 | PMC |
| http://dx.doi.org/10.1038/s41579-022-00772-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Immunoinformatic Approach for Identifying and Designing Conserved Multi-Epitope Vaccines for Coronaviruses.
Biomedicines
November 2024
Center for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.
Background/objectives: The COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has exposed the vulnerabilities and unpreparedness of the global healthcare system in dealing with emerging zoonoses. In the past two decades, coronaviruses (CoV) have been responsible for three major viral outbreaks, and the likelihood of future outbreaks caused by these viruses is high and nearly inevitable. Therefore, effective prophylactic universal vaccines targeting multiple circulating and emerging coronavirus strains are warranted.
View Article and Find Full Text PDFDiscovery and characterization of a pan-betacoronavirus S2-binding antibody.
Structure
November 2024
Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 73232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Computer Science, Vanderbilt University, Nashville, TN 37232, USA; Center for Structural Biology, Vanderbilt University, Nashville, TN 37232, USA; Program in Computational Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:
Article Synopsis
- - The research focuses on developing pan-coronavirus interventions by identifying 50 antibodies from human B cells, particularly highlighting the antibody 54043-5, which binds to a common part of spike proteins in various coronaviruses.
- - A structural analysis revealed that 54043-5 recognizes a specific, highly conserved region of the S2 subunit in SARS-CoV-2, which is critical for understanding how this antibody can potentially provide protection.
- - Although 54043-5 does not neutralize the virus directly, it activates immune responses that help combat infections, and certain modifications to this antibody showed protective effects in mouse models of SARS-CoV-2 disease.
Development and evaluation of vaccination strategies for addressing the continuous evolution SARS-CoV-2 based on recombinant trimeric protein technology: Potential for cross-neutralizing activity and broad coronavirus response.
Heliyon
July 2024
Reproductive Medicine Center, Guangdong Second Provincial General Hospital, #466 Xin-Gang-Zhong-Lu, Haizhu District, Guangzhou, 510317, China.
Article Synopsis
- Some vaccines aren’t working as well against the Omicron variant of COVID-19, so new vaccines are needed.
- Researchers created different types of vaccines and tested them in mice to see which ones helped produce antibodies that fight the virus.
- They found specific combinations of vaccines were better at working against Omicron and suggested new vaccine guidelines to help boost immunity.
Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes.
Cell Rep
June 2024
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Scripps Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA; Multi-Omics Vaccine Evaluation Consortium, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address:
The development of vaccines and therapeutics that are broadly effective against known and emergent coronaviruses is an urgent priority. We screened the circulating B cell repertoires of COVID-19 survivors and vaccinees to isolate over 9,000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs), providing an expansive view of the SARS-CoV-2-specific Ab repertoire. Among the recovered antibodies was TXG-0078, an N-terminal domain (NTD)-specific neutralizing mAb that recognizes diverse alpha- and beta-coronaviruses.
View Article and Find Full Text PDFHigh frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4 and CD8 memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients.
Front Immunol
April 2024
Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA, United States.
Background: Cross-reactive SARS-CoV-2-specific memory CD4 and CD8 T cells are present in up to 50% of unexposed, pre-pandemic, healthy individuals (UPPHIs). However, the characteristics of cross-reactive memory CD4 and CD8 T cells associated with subsequent protection of asymptomatic coronavirus disease 2019 (COVID-19) patients (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!